News
1d
Medpage Today on MSNEnergy Drinks and Blood Cancer; Groups Slam MAHA Report; FDA Warns of Falsified DataAnd Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...
As the administration pushes for a return to US manufacturing, outsourcing agreements with domestic manufacturers are ...
2d
GlobalData on MSNOrionis and Genentech link on oncology small-molecule glue medicinesThe partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.
Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase ...
Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...
The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...
Columvi combo for relapsed diffuse large B-cell lymphoma faces approval hurdle. Discover implications for U.S. Read more here ...
Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...
A new promo for Roche’s blockbuster hemophilia A drug Hemlibra focuses less on those with the genetic bleeding disorder and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results